Paul Feldman
Head of Discovery and Translational Medicine
organic chemistry
Intarcia Therapeutics
United States of America
Biography
Dr. Paul Feldman joined Intarcia in September 2015 as Head of Discovery and Translational Medicine. Dr. Feldman assumed this new role following Intarcia’s acquisition of Phoundry Pharmaceuticals, Inc., a peptide therapeutic discovery company, where he was a co-founder and CEO. Prior to his work at Phoundry, Dr. Feldman worked for GlaxoSmithKline, ultimately as a senior vice president, and some of his accomplishments included: contributing to the discovery and development of multiple medicines, leading national and international multi-disciplinary discovery and early development groups, managing several key multi-national business collaborations, and serving as the head for GlaxoSmithKline’s Research Triangle Park site. Dr. Feldman has more than 100 scientific disclosures (patents, scientific articles, book chapters, and invited lectures), and has been an adjunct Professor of Chemistry for Duke and North Carolina State Universities.
Research Interest
He has served in multiple leadership roles for the executive committee of the Division of Organic Chemistry of the American Chemical Society, and is currently an editor for “Organic Reactions”. He received a B.S in chemistry from Duke University and a Ph.D. in organic chemistry from the University of California, Berkeley.
